ERAS
Price
$1.57
Change
-$0.01 (-0.63%)
Updated
Aug 28 closing price
Capitalization
445.36M
68 days until earnings call
PVLA
Price
$51.30
Change
-$5.15 (-9.12%)
Updated
Aug 28 closing price
Capitalization
567.36M
Interact to see
Advertisement

ERAS vs PVLA

Header iconERAS vs PVLA Comparison
Open Charts ERAS vs PVLABanner chart's image
Erasca
Price$1.57
Change-$0.01 (-0.63%)
Volume$338.84K
Capitalization445.36M
Palvella Therapeutics
Price$51.30
Change-$5.15 (-9.12%)
Volume$90.79K
Capitalization567.36M
ERAS vs PVLA Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PVLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. PVLA commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and PVLA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (ERAS: $1.57 vs. PVLA: $51.30)
Brand notoriety: ERAS and PVLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 44% vs. PVLA: 55%
Market capitalization -- ERAS: $445.36M vs. PVLA: $567.36M
ERAS [@Biotechnology] is valued at $445.36M. PVLA’s [@Biotechnology] market capitalization is $567.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whilePVLA’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • PVLA’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than PVLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 6 TA indicator(s) are bullish while PVLA’s TA Score has 3 bullish TA indicator(s).

  • ERAS’s TA Score: 6 bullish, 3 bearish.
  • PVLA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than PVLA.

Price Growth

ERAS (@Biotechnology) experienced а +4.67% price change this week, while PVLA (@Biotechnology) price change was -0.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.15%. For the same industry, the average monthly price growth was +15.07%, and the average quarterly price growth was +29.12%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-1.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PVLA($567M) has a higher market cap than ERAS($445M). PVLA YTD gains are higher at: 327.500 vs. ERAS (-37.450). PVLA has higher annual earnings (EBITDA): -23.27M vs. ERAS (-135.93M). ERAS has more cash in the bank: 301M vs. PVLA (70.4M). ERAS (0) and PVLA (0) have equivalent revenues.
ERASPVLAERAS / PVLA
Capitalization445M567M78%
EBITDA-135.93M-23.27M584%
Gain YTD-37.450327.500-11%
P/E RatioN/A14.22-
Revenue00-
Total Cash301M70.4M428%
Total Debt49.4MN/A-
FUNDAMENTALS RATINGS
PVLA: Fundamental Ratings
PVLA
OUTLOOK RATING
1..100
22
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASPVLA
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 29 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PVLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGLTX22.820.19
+0.84%
Janus Henderson VIT Glb Tech&Innvt Instl
CGAEX12.94N/A
N/A
Calvert Global Energy Solutions A
GCSAX28.21N/A
N/A
Goldman Sachs Small Cap Eq Insghts A
RPNLX13.81N/A
N/A
RiverPark/Next Century Lg Gr Inst
REEAX15.27N/A
N/A
RBC Emerging Markets Equity A

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-0.63%
XNCR - ERAS
53%
Loosely correlated
+0.37%
RVMD - ERAS
53%
Loosely correlated
+0.75%
OCUL - ERAS
53%
Loosely correlated
+1.62%
BEAM - ERAS
51%
Loosely correlated
-0.06%
IRON - ERAS
50%
Loosely correlated
-0.48%
More

PVLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PVLA has been loosely correlated with DRMA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if PVLA jumps, then DRMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PVLA
1D Price
Change %
PVLA100%
-9.12%
DRMA - PVLA
42%
Loosely correlated
+1.13%
OCUL - PVLA
35%
Loosely correlated
+1.62%
OBIO - PVLA
34%
Loosely correlated
-4.58%
ERAS - PVLA
32%
Poorly correlated
-0.63%
BCYC - PVLA
32%
Poorly correlated
+1.14%
More